Pharmaceuticals, Biotechnology and Life Sciences
Roche said on Monday that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq (atezolizumab) for metastatic urothelial carcinoma (mUC).
Bristol-Myers Squibb (BMS) and GeneCentric Diagnostics have teamed up to explore the possibility of GeneCentric’s Cancer Subtype Platform (CSP) could identify translational biomakers for Opdivo, that could help for future clinical trials.
Gilead Sciences has strengthened its lines with newly appointed Hematology and Oncology Therapeutic Area Head, who came from Novartis.
Oasmia Pharmaceutical, a developer of a new generation of drugs within human and veterinary oncology, today presented positive results from…
Novartis gets FDA Priority Review for first-line treatment of HR+/HER2-advanced breast cancer
Advanced Oncotherapy , the developer of proton therapy systems for cancer treatment, has announced on Tuesday that planning permission for the Harley Street site was granted.
Important clinical study results from one of Eli Lilly and Company’s ongoing immuno-oncology collaborations with Merck (known as MSD outside…
AstraZeneca and MedImmune, its global biologics research and development arm, on Wednesday announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for durvalumab (MEDI4736), an investigational human monoclonal antibody directed against programmed death ligand-1 (PD-L1), for the treatment of patients with PD-L1 positive inoperable or metastatic urothelial bladder cancer whose tumour has progressed during or after one standard platinum-based regimen.
By Pamela Barbaglia LONDON (Reuters) – European buyout firm Charterhouse [CHCAP.UL] is preparing for the sale of its Italian generic…
Midatech Pharma, the international specialty pharmaceutical company focused on developing and commercialising products in oncology and other therapeutic areas, has entered into a licensing agreement with Emergex Vaccines Limited, a private UK biotechnology company focused on infectious diseases utilising Midatech’s gold nanoparticle technology.